JP2016523511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523511A5 JP2016523511A5 JP2016506657A JP2016506657A JP2016523511A5 JP 2016523511 A5 JP2016523511 A5 JP 2016523511A5 JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016523511 A5 JP2016523511 A5 JP 2016523511A5
- Authority
- JP
- Japan
- Prior art keywords
- pairs
- indicator
- region
- cancer cells
- loh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019085187A JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809105P | 2013-04-05 | 2013-04-05 | |
| US61/809,105 | 2013-04-05 | ||
| US201361913762P | 2013-12-09 | 2013-12-09 | |
| US61/913,762 | 2013-12-09 | ||
| PCT/US2014/033014 WO2014165785A2 (en) | 2013-04-05 | 2014-04-04 | Methods and materials for assessing homologous recombination deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085187A Division JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523511A JP2016523511A (ja) | 2016-08-12 |
| JP2016523511A5 true JP2016523511A5 (enExample) | 2017-03-16 |
| JP6625045B2 JP6625045B2 (ja) | 2019-12-25 |
Family
ID=51659359
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506657A Active JP6625045B2 (ja) | 2013-04-05 | 2014-04-04 | 相同組換え欠損を評価するための方法および材料 |
| JP2019085187A Active JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
| JP2020194936A Active JP7522643B2 (ja) | 2013-04-05 | 2020-11-25 | 相同組換え欠損を評価するための方法および材料 |
| JP2022169085A Active JP7641938B2 (ja) | 2013-04-05 | 2022-10-21 | 相同組換え欠損を評価するための方法および材料 |
| JP2025027653A Pending JP2025090619A (ja) | 2013-04-05 | 2025-02-25 | 相同組換え欠損を評価するための方法および材料 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085187A Active JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
| JP2020194936A Active JP7522643B2 (ja) | 2013-04-05 | 2020-11-25 | 相同組換え欠損を評価するための方法および材料 |
| JP2022169085A Active JP7641938B2 (ja) | 2013-04-05 | 2022-10-21 | 相同組換え欠損を評価するための方法および材料 |
| JP2025027653A Pending JP2025090619A (ja) | 2013-04-05 | 2025-02-25 | 相同組換え欠損を評価するための方法および材料 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20140363521A1 (enExample) |
| EP (2) | EP2981624B1 (enExample) |
| JP (5) | JP6625045B2 (enExample) |
| AU (3) | AU2014248007B2 (enExample) |
| CA (1) | CA2908745C (enExample) |
| DK (1) | DK2981624T3 (enExample) |
| ES (1) | ES2777228T3 (enExample) |
| PT (1) | PT2981624T (enExample) |
| WO (1) | WO2014165785A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| KR20190002733A (ko) | 2010-12-30 | 2019-01-08 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| EP3660161B1 (en) | 2011-12-21 | 2024-07-31 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| EP4023765A1 (en) | 2013-12-09 | 2022-07-06 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| ES2800673T3 (es) | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| ES2989276T3 (es) * | 2014-12-05 | 2024-11-25 | Found Medicine Inc | Análisis multigénico de muestras tumorales |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| US20180148792A1 (en) | 2015-05-19 | 2018-05-31 | T.S. Sridhar | Method for Identification of a Deficient BRCA1 Function |
| AU2016348401A1 (en) * | 2015-11-03 | 2018-05-24 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (CTCs) in metastatic disease to characterize disease heterogeneity |
| WO2017106365A1 (en) * | 2015-12-14 | 2017-06-22 | Myriad Genetics, Inc. | Methods for measuring mutation load |
| WO2017191074A1 (en) * | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| EP3400311A4 (en) * | 2016-01-06 | 2019-07-03 | Epic Sciences, Inc. | GENOMIC INDIVIDUAL CELL PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN METASTASIC DISEASE TO CHARACTERIZE THE DISEASE HETEROGENICITY |
| WO2017165270A1 (en) * | 2016-03-21 | 2017-09-28 | Myriad Genetics, Inc. | Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer |
| WO2017178509A1 (en) | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| WO2017191076A1 (en) | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| EP3478286B1 (en) * | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| EP3802923A4 (en) | 2018-06-11 | 2022-03-16 | Foundation Medicine, Inc. | COMPOSITIONS AND METHODS FOR ASSESSING GENOMIC ALTERATIONS |
| WO2020137076A1 (ja) * | 2018-12-28 | 2020-07-02 | 国立大学法人 東京大学 | Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法 |
| JP7368483B2 (ja) | 2019-02-12 | 2023-10-24 | テンパス ラブズ，インコーポレイテッド | 相同組換え欠損を推定するための統合された機械学習フレームワーク |
| ES2989374T3 (es) | 2019-12-10 | 2024-11-26 | Tempus Ai Inc | Sistemas y procedimientos para predecir el estado de deficiencia de recombinación homóloga de una muestra |
| JP2023506084A (ja) * | 2019-12-16 | 2023-02-14 | アジレント・テクノロジーズ・インク | ゲノム瘢痕アッセイ及び関連する方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN111883211B (zh) * | 2020-08-07 | 2021-04-23 | 张哲� | 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法 |
| US11718869B2 (en) * | 2020-08-12 | 2023-08-08 | Zhenyue Biotechnology Jiangsu Co., Ltd. | Method and kit for determining genome instability based on next generation sequencing (NGS) |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| EP4274908A1 (en) * | 2021-01-10 | 2023-11-15 | Act Genomics (IP) Limited | Homologous recombination deficiency determining method and kit thereof |
| BE1029144B1 (fr) | 2021-02-25 | 2022-09-20 | Oncodna | Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé |
| CN112820351A (zh) * | 2021-03-01 | 2021-05-18 | 江苏医联生物科技有限公司 | 检测肿瘤患者的突变和hrd评分指导用药的方法 |
| WO2022272310A1 (en) * | 2021-06-25 | 2022-12-29 | Foundation Medicine, Inc. | System and method of classifying homologous repair deficiency |
| EP4444914A1 (en) * | 2021-12-08 | 2024-10-16 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency in breast cancer subtypes |
| KR102523938B1 (ko) * | 2022-02-04 | 2023-04-19 | 가톨릭대학교 산학협력단 | 상동 재조합 결핍증 예측 모델의 모델링 방법 |
| EP4605937A1 (en) | 2022-10-19 | 2025-08-27 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| MX9206577A (es) | 1991-11-15 | 1993-05-01 | Smithkline Beecham Corp | COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| ATE478664T1 (de) | 2000-12-01 | 2010-09-15 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| US7754684B2 (en) | 2003-06-11 | 2010-07-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| DE04777189T1 (de) | 2003-07-02 | 2011-04-07 | Solux Corporation, San Diego | Thermisch stabiles kristallines epirubicin-hydrochlorid und herstellungsverfahren dafür |
| ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
| DE602004015811D1 (de) | 2003-08-13 | 2008-09-25 | Univ South Florida | Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden |
| MX2007015852A (es) | 2005-06-30 | 2008-02-22 | Bionumerik Pharmaceuticals Inc | Analogos de platino con ligandos de monoazol. |
| KR100925337B1 (ko) * | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| WO2011160063A2 (en) | 2010-06-18 | 2011-12-22 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| EP3415915B1 (en) * | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
-
2014
- 2014-04-04 AU AU2014248007A patent/AU2014248007B2/en active Active
- 2014-04-04 EP EP14779403.6A patent/EP2981624B1/en active Active
- 2014-04-04 US US14/245,576 patent/US20140363521A1/en not_active Abandoned
- 2014-04-04 ES ES14779403T patent/ES2777228T3/es active Active
- 2014-04-04 DK DK14779403.6T patent/DK2981624T3/da active
- 2014-04-04 JP JP2016506657A patent/JP6625045B2/ja active Active
- 2014-04-04 CA CA2908745A patent/CA2908745C/en active Active
- 2014-04-04 PT PT147794036T patent/PT2981624T/pt unknown
- 2014-04-04 EP EP19216740.1A patent/EP3693475A1/en active Pending
- 2014-04-04 WO PCT/US2014/033014 patent/WO2014165785A2/en not_active Ceased
-
2017
- 2017-07-17 US US15/651,652 patent/US20180030544A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2019085187A patent/JP7522539B2/ja active Active
-
2020
- 2020-06-17 AU AU2020204028A patent/AU2020204028B2/en active Active
- 2020-11-25 JP JP2020194936A patent/JP7522643B2/ja active Active
-
2021
- 2021-06-21 US US17/353,279 patent/US20210310079A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211880A patent/AU2022211880B2/en active Active
- 2022-10-21 JP JP2022169085A patent/JP7641938B2/ja active Active
-
2025
- 2025-02-25 JP JP2025027653A patent/JP2025090619A/ja active Pending
- 2025-03-24 US US19/088,496 patent/US20250223655A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523511A5 (enExample) | ||
| FI2794907T4 (fi) | Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi | |
| ES2946251T3 (es) | Métodos y materiales para evaluar la deficiencia de recombinación homóloga | |
| ES2777228T3 (es) | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer | |
| ES2862331T3 (es) | Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer | |
| US20180163271A1 (en) | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity | |
| JP2017512491A5 (enExample) | ||
| Macerelli et al. | Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? | |
| Liu et al. | Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing | |
| Duraturo et al. | Coexistence of MLH3 germline variants in colon cancer patients belonging to families with Lynch syndrome-associated brain tumors | |
| CN108603231B (zh) | 检测癌症复发的方法 | |
| McDonald et al. | Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation | |
| Haerian et al. | Association of 8q24. 21 rs10505477-rs6983267 haplotype and age at diagnosis of colorectal cancer | |
| Jiang et al. | Identification of a novel fusion gene (HLA-E and HLA-B) by RNA-seq analysis in esophageal squamous cell carcinoma | |
| Shi et al. | Prognostic Model for Clear-cell Renal Cell Carcinoma Based on Natural Killer Cell-related Genes. | |
| Fang et al. | ‘Druggable’alterations detected by Ion Torrent in metastatic colorectal cancer patients | |
| Sparano | Defining a role and predicting benefit from platinum-based therapy in breast cancer: an evolving story | |
| Gill | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies | |
| US20240189450A1 (en) | Methods for treating cancers | |
| Gosia et al. | Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches | |
| NZ728326B2 (en) | Methods and materials for assessing homologous recombination deficiency | |
| NZ766822B2 (en) | Methods and materials for assessing homologous recombination deficiency | |
| Richardson et al. | Homologous recombination deficiency (HRD) score predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer | |
| Fedorova et al. | MicroRNA miR-152 Methylation in Patients With Ovarian Cancer: Prognostic Potential Analysis | |
| Zhou et al. | Systematic analysis of tumor-infiltrating immune cells in human endometrial cancer: a retrospective study |